Novel Therapy for Diabetes to be Presented at the WCIDT, London

London – September 25 2015 – The DIAMOND system for treatment of type 2 diabetes will be presented at the 3rd World Congress on Interventional Therapies for Type 2 Diabetes, taking place in London on September 28 – 30.  A stellar faculty of world leading experts will discuss evidence on clinical outcomes and mechanisms of action of bariatric/metabolic surgery and new device-based interventions, with the overarching aim to craft an agenda of research priorities and health policy initiatives.  The annual congress will attract an international audience of healthcare professionals in the field on endocrinology, diabetes and metabolic surgery as well as leading policy makers.

The latest data on gastric electrical stimulation, delivered by MetaCure’s DIAMOND device, will be presented by Prof. Harold Lebovitz as part of the Clinical Track Session on Novel Operations and Device Based Interventions, chaired by Prof. Stephan Bornstein and Prof. John Morton. A satellite session will also present the principles of the therapy, clinical experiences and further clinical data. Additionally, five scientific abstracts will share new clinical data. The program schedule is provided below.

Clinical track session, Monday September 28
Hall A 16:30 – 18:30, Session 3: Clinical Track
Novel Operations and Device Based Interventions
Chairmen: Stephan Bornstein, UK; John Morton, USA

 

Satellite symposium, Tuesday September 29
Hall B 19:45 – 20:45, light dinner service from 19:15 by our booth
DIAMOND® by MetaCure: Minimally Invasive Treatment for Type 2 Diabetes by Electrical Modulation of Physiological Regulatory Systems
Chairman: Prof. Harold Lebovitz
Speakers: Prof. Harold Lebovitz, Prof. Wieslaw Tarnowski, Prof. Shlomo Ben-Haim
Panelists: Prof. John Dixon, Prof. George Alberti, Prof. Andreas Barthel
Program:

 

The following scientific abstracts will be presented at e-poster terminals at the congress in Level -1 (Plaza Suites) and Level -3 (Westminster Ballroom Foyer):

Interested parties are welcome at MetaCure’s booth located at Plaza Suites, Level -1 (booth #06).

Learn more about the DIAMOND system at www.MetaCure.com/DIAMOND.

Information about the 3rd World Congress on Interventional Therapies for Type 2 Diabetes is available at www.wcitt2d.org.

 

 

About type 2 diabetes
Type 2 diabetes is a metabolic disorder characterized by hyperglycemia resulting from inadequate insulin secretion or insulin resistance. The most common form of diabetes, it represents 90% of all cases. Often referred to as a pandemic, it is estimated that over 400 million people worldwide are affected by diabetes, with management costs exceeding $800 billion annually.

 

About DIAMOND therapy
DIAMOND therapy is delivered via an implantable medical device which has the potential to be used as an alternative to insulin.  The safety and efficacy of DIAMOND therapy have been validated in clinical trials involving over 300 patients, including a pilot study which demonstrated a comparable effectiveness to insulin treatment, but avoiding many side-effects and the inconvenience of frequent blood tests and injections.  Designed to treat type 2 diabetes in obese patients who are refractory to oral medication, DIAMOND therapy is delivered via a small pacemaker-like device implanted in the abdomen, which delivers electrical signals to the stomach when eating, improving glycemic control and promoting weight loss.  DIAMOND has received CE mark and is approved for sale in Europe, Australia and other international markets; it is currently not approved for use in the USA.  For more information, visit www.MetaCure.com/DIAMOND.

 

About MetaCure
MetaCure, a member of the Hobart Group companies, aims to provide a better way to manage type 2 diabetes, focusing on the impact on the day-to-day lives of patients. It develops, produces and markets the DIAMOND therapy, an alternative to insulin delivered via a proprietary implantable device.  For more information, visit MetaCure.com.

 

About Hobart Group
The Hobart Group develops and commercializes medical technologies which target top healthcare markets with significant unmet needs.  Its growing portfolio of companies covers the areas of cardiology, diabetes, oncology, neurology and rehabilitation.  Together, Hobart Group companies have over 200 scientists, engineers, regulatory and business experts across four continents, benefitting from clinical expertise and extensive regulatory and international market knowledge across Europe, the USA and Asia.  For more information, visit www.Hobart-Group.com.

 

For media enquiries
Mrs. Sharon Alon
Email: Media@MetaCure.com
Tel: +1 347-761-3342
Website: www.MetaCure.com